- Home
- SLN
SLN
Silence Therapeutics Plc American Depository Share
as 03-28-2025 2:42pm EST
| Founded: | 1994 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $40.80 | AVG Volume (30 days): | 183.6K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.19 - $24.38 | Next Earning Date: | 05-15-2025 |
| Revenue: | $43,258,000 | Revenue Growth: | 36.71% |
| Revenue Growth (this year): | -25.23% | Revenue Growth (next year): | N/A |
Latest Silence Therapeutics Plc American Depository Share News
SLN Breaking Stock News: Dive into SLN Ticker-Specific Updates for Smart Investing
Simply Wall St.
23 days ago
Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN)
Business Wire
24 days ago
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
Zacks
25 days ago
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
Simply Wall St.
a month ago
Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Business Wire
a month ago
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Business Wire
a month ago
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
MT Newswires
2 months ago
Silence Therapeutics Shares Fall After Goldman Sachs Initiates Coverage at Sell
Simply Wall St.
3 months ago
Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses
Compare SLN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLN Silence Therapeutics Plc American Depository Share - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.